ABSTRACT
Introduction Breast cancer remains a leading cause of cancer deaths; however, recent improvements in treatment have improved survivorship. As a result of this improvement, more individuals are living with the long-term side effects of cancer treatment. Therefore, methods that incorporate lifestyle and mind-body approaches are becoming increasingly used in the patient treatment pathway.
Methods In this study, PranaScience Institute will develop and test a group video mobile application for Yogic Breathing (YB). YB is shown to reduce symptomatic conditions associated with several conditions including breast cancer. For this initial feasibility study, PranaScience will collaborate with the Medical University of South Carolina to implement the study app-based program in breast cancer survivors. This research is aimed to understand if the YB could be delivered via an app, if participants are able to practice it satisfactorily, and if there is any symptom relief by the YB practice. In the control group, participants will be directed to the Attention Control (AC) feature of the app, which guides users to focus on a mindfulness activity not involving YB. Participants will be randomly assigned to the YB or AC study plan (N=20 per group). Breast cancer survivors who have completed radiation therapy within last 6 months will be recruited for this study and provided access to the app for a 12-week program. The study app will record total practice times. Virtual visits by a study yoga instructor during group video sessions will measure participant compliance with proper technique. Feasibility will be examined by evaluating intervention delivery factors and resource needs. Acceptability of using the mobile study app to support symptom management will be evaluated using a satisfaction and system usability scale. Behavioral survey measures will help guide effect sizes and power calculations for the next larger-scale study. Biomarkers in the saliva (tumor suppressors, cytokines), and fingernails (cortisol, differential proteomics) will be measured at baseline and end of study at 12 weeks.
Discussion All findings from this pilot study will be synthesized to refine the mobile study app in preparation for large-scale evaluation in Phase II involving all-study site participants with cancer. ClinicalTrials.gov Identifier NCT05161260.
Competing Interest Statement
SB is the founder and CEO of PranaScience Institute, the small business entity that has received the funding to conduct this research.
Clinical Trial
ClinicalTrials.gov Identifier NCT05161260
Funding Statement
SB is funded through the National Cancer Institute of the National Institutes of Health via the Small Business Technology Transfer Research grants awarded to PranaScience Institute (1R41CA254557 and 3R41CA254557). https://reporter.nih.gov/search/79cEF_BFA06n0MTykQFkCA/projects The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This protocol was approved by the Institutional Review Board committees at Advarra (Pro00050387), and the Medical University of South Carolina (Pro00108511).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
Deidentified research data will be made publicly available when the study is completed and published.
List of Abbreviations
- AC
- attention control
- DMBT1
- deleted in malignant brain tumor 1
- ECOG
- Eastern Cooperative Oncology Group
- ELISA
- enzyme-linked immunosorbent assay
- IL
- interleukin
- MCP1
- monocyte chemotactic protein 1
- MDASI
- MD Anderson Symptom Inventory
- NGF
- Nerve Growth Factor
- SCTR
- South Carolina Clinical and Translational Research Institute
- SUS
- system usability scale
- TMP
- Thirumoolar Pranayamam
- YB
- yogic breathing,
